Armata Pharmaceuticals (ARMP) Income towards Parent Company (2013 - 2026)

Armata Pharmaceuticals has disclosed Income towards Parent Company across 14 years of filings, most recently posting -$14.3 million for Q1 2026.

• Income towards Parent Company for Q1 2026 came in at -$14.3 million, down 21.63% year-over-year; the trailing twelve-month figure through Mar 2026 was -$55.8 million (down 5.83% YoY), and the FY2025 annual result was -$53.2 million, changed 0.09% from the prior year.
• Income towards Parent Company came in at -$14.3 million for Q1 2026 at Armata Pharmaceuticals, up from -$18.7 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of -$8.6 million in Q3 2022 to a low of -$18.7 million in Q4 2025.
• The 5-year median for Income towards Parent Company is -$11.5 million (2023), against an average of -$11.8 million.
• Across the five-year window, Income towards Parent Company sank 70.56% in 2022 and rose 26.08% in 2025, its largest moves.
• Armata Pharmaceuticals' Income towards Parent Company stood at -$10.3 million in 2022, then dropped by 6.27% to -$11.0 million in 2023, then declined by 26.07% to -$13.8 million in 2024, then plunged by 35.01% to -$18.7 million in 2025, then gained by 23.12% to -$14.3 million in 2026.
• The last three Income towards Parent Company figures came in at -$14.3 million (Q1 2026), -$18.7 million (Q4 2025), and -$12.1 million (Q3 2025), per Business Quant data.